Lung Cancer Diagnostics Market Growth and Forecast 2024-2030

Lung cancers consequences from uncontrolled cell growth, forming loads referred to as tumors. Typically originating from the lining cells of the airlines (bronchi and bronchioles), it is frequently referred to as bronchogenic cancers or carcinoma. Cigarette smoking is the primary cause, contributing to approximately 90% of instances, at the same time as different factors like lung disease, a prior cancer history, and air pollutants also play a role. Symptoms range depending on tumor location and spread, together with shortness of breath, coughing blood, chest pain, headache, and dysphagia.

Expert Insights: Ask Analyst or Download Full Report with TOC and Figures:

Increasing R&D efforts for early cancer detection are predicted to reinforce the global lung cancer diagnostic market. Researchers at MIT advanced a nanoparticle-primarily-based urine check in April 2020 for early lung cancer detection. This approach detects biomarkers produced by peptide-covered nanoparticles interacting with tumor-associated proteases. Validated in two mouse models, the test identified tumors as small as 2.18 mm. Its noninvasive nature reduces false positives from conventional tests, enhancing early tumor detection.

The global lung cancer diagnostics market reached US$ 18.2 Billion in 2023 and is projected to develop at a CAGR of 7.23% from 2024 to 2030. Increasing lung cancer rates, driven by lifestyle shifts and heightened tobacco use, will raise the demand for surgical devices, fostering a boom in the lung cancer diagnostic market. Lifestyle choices, like smoking, once symbolic of freedom, now pose subnational health risks. Smoking and dietary and exercise behaviors contribute to this complicated issue. Its vast prevalence poses a widespread public heath venture and is a primary cause of lung cancer. The surge in tobacco intake, shaped by evolving lifestyles, is anticipated to propel market growth. In May 2022, according to a WHO, tobacco claims over 8 million lives annually, with 7 million from direct use and 1.2 million from secondhand smoke.

Request a free sample copy of the report:

Imaging tests represent one of the leading segments within the global lung cancer diagnostics market.

Imaging tests are at the forefront of the global lung cancer diagnostics market, pivotal in early detection, diagnosis, and disease monitoring. These tests, which include chest X-rays, computed tomography (C.T.) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, provide detailed images of the lungs, allowing healthcare professionals to identify abnormalities such as tumors or nodules. With advancements in imaging technology and increased accessibility to these tests, they have become indispensable tools in the fight against lung cancer, facilitating timely intervention and improving patient outcomes in the ever-evolving landscape of cancer diagnosis and treatment.

Non-Small Cell Lung Cancer (NSCLC) occupies a significant position within the global lung cancer diagnostics market.

Non-Small Cell Lung Cancer (NSCLC) is one of the most significant components in the global lung cancer diagnostics market. As the most common type of lung cancer, NSCLC comprises various subtypes, each requiring precise diagnostic approaches for effective management. Diagnostic methods such as imaging tests, molecular testing, and biopsies are crucial in accurately identifying NSCLC and determining optimal treatment strategies tailored to individual patients. With advancements in diagnostic technologies and therapies, addressing NSCLC holds paramount importance in improving patient outcomes and reducing the burden of lung cancer worldwide, positioning it as a key focus area in the ongoing evolution of lung cancer diagnostics.

Hospital-associated hospital laboratories are extensively utilized in the global lung cancer diagnostics market.

Hospital-associated labs play a pivotal role in the global lung cancer diagnostics market. These facilities are essential hubs for conducting various diagnostic tests, including imaging studies, molecular analyses, and tissue biopsies, which are crucial for accurately detecting and characterizing lung cancer. Their close integration with clinical care settings enables swift sample processing and timely reporting of results, facilitating prompt treatment decisions and patient management. As key contributors to the diagnostic pathway, hospital-associated labs significantly improve patient outcomes and advance research efforts in the ongoing fight against lung cancer, underscoring their integral role in the healthcare ecosystem.

The United States could maintain its dominance in the global lung cancer diagnostics market.

The United States is poised to uphold its leading position in the global lung cancer diagnostics market. Renowned for its advanced healthcare infrastructure, the U.S. boasts cutting-edge diagnostic technologies and widespread access to screening and testing services. Additionally, the country’s robust research and development efforts and substantial investments in cancer research further solidify its dominance. With a focus on innovation and a commitment to improving diagnostic accuracy and patient outcomes, the United States is positioned to sustain its leadership in lung cancer diagnostics, driving advancements that benefit patients worldwide.

Key Players

The global market for lung cancer diagnostics includes prominent firms such as Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Sanofi S.A., Agilent Technologies, and bioMérieux.

Related Reports

Lung Cancer Screening Market:

Global Teleradiology Market:

Non-Small Cell Lung Cancer Market:

Molecular Diagnostics Market:

Diagnosis Test Type – Market breakup in 5 viewpoints:

1.    Imaging Test

2.    Biopsy

3.    Sputum Cytology

4.    Molecular Test

5.    Others

Cancer Type – Market breakup in 2 viewpoints:

1.    Non- Small Cell Lung Cancer

2.    Small Cell Lung Cancer

End-User – Market breakup in 5 viewpoints:

1.    Hospital Associated Labs

2.    Independent Diagnostic Laboratories

3.    Diagnostic Imaging Centers

4.    Cancer Research Institutes

5.    Others

Country – Market breakup in 25 Countries:

1.    North America

1.1    United States

1.2    Canada

2.    Europe

2.1    France

2.2    Germany

2.3    Italy

2.4    Spain

2.5    United Kingdom

2.6    Belgium

2.7    Netherlands

2.8    Turkey

3.    Asia Pacific

3.1    China

3.2    Japan

3.3    India

3.4    South Korea

3.5    Thailand

3.6    Malaysia

3.7    Indonesia

3.8    Australia

3.9    New Zealand

4.    Latin America

4.1    Brazil

4.2    Mexico

4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia

5.2    UAE

5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview

•    Recent Development

•    Revenue Analysis

Company Analysis:

1.    llumina

2.    Abbott Laboratories

3.    Thermo Fisher Scientific, Inc.

4.    QIAGEN N.V.

5.    Roche Holding AG.

6.    Sanofi S.A.

7.    Agilent Technologies

8.    bioMérieux.

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button